Oculis Holding AG (OCS)
| Previous close | 11.10 |
| Open | 11.35 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's range | 11.00 - 11.35 |
| 52-week range | 6.26 - 14.50 |
| Volume | |
| Avg. volume | 16,823 |
| Market cap | 413.177M |
| Beta (5Y monthly) | 0.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.35 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 33.23 |
GlobeNewswireOculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase
Following the achievement of two positive key late-stage clinical milestones on its lead product candidate OCS-01 and recent listing on NASDAQ, Oculis is strengthening its executive leadership team with the appointment of Rebecca Weil, Ph.D., seasoned global ophthalmology commercial executive, as Chief Commercial OfficerOCS-01’s recent positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) and in Phase 3 OPTIMIZE trial for inflammation and pain following catar
- GlobeNewswire
Oculis to Present at Upcoming September Investor Conferences
ZUG, Switzerland, and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference Format: Company presentation Presentation date and time:
- GlobeNewswire
Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back of the eye indications: positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) announced in May, and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery announced in AugustAdvancing clinical programs with OCS-01, OCS-02 and OCS-05, including first patient enrolled in the investigator-initiated LEOPARD
